Premium
Large‐scale production of monoclonal antibodies in suspension culture
Author(s) -
Backer M. P.,
Metzger L. S.,
Slaber P. L.,
Nevitt K. L.,
Boder G. B.
Publication year - 1988
Publication title -
biotechnology and bioengineering
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.136
H-Index - 189
eISSN - 1097-0290
pISSN - 0006-3592
DOI - 10.1002/bit.260320807
Subject(s) - aeration , sparging , suspension culture , monoclonal antibody , cell culture , suspension (topology) , bioreactor , impeller , chemistry , chromatography , agitator , biology , antibody , mass transfer , immunology , mechanics , physics , mathematics , organic chemistry , homotopy , pure mathematics , genetics
Monoclonal antibodies are being manufactured for clinical trials in suspension culture at the 1300‐L scale. Suspension culture offers some advantages relative to high‐density mammalian cell culture methods; in particular, the ability to closely monitor the behavior of cells in a homogeneous environment. Computer control and on‐line mass spectrography of exit gases provide instantaneous information about the culture metabolic activity. Air sparging and agitation by marine impeller provide aeration sufficient to maintain a constant dissolved oxygen tension at cell concentrations up to 5.0 × 10 6 cells/mL without causing apparent cell damage.